MedTrace Logo

Efficacy and Safety of Intravitreal Bevacizumab for Threshold ROP.

NCT01707745 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2012-10-16

No results posted yet for this study

Summary

Prospective study to evaluate the efficacy and safety of intravitreal bevacizumab In retinopathy of prematurity (ROP).

Bevacizumab 0.75 mg in 0.03 ml was given to stage 2+ or stage 3+ ROP in Zone I or Zone II.

Conditions

  • Stage 2+ or Stage 3+ Retinopathy of Prematurity in Zone I or Zone II.

Interventions

PROCEDURE

Intravitreal Bevacizumab

Sponsors & Collaborators

  • Sivakami A Pai

    lead OTHER_GOV

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
32 Weeks
Max Age
42 Weeks
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2012-12-31
Completion
2012-12-31

Countries

  • United Arab Emirates

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01707745 on ClinicalTrials.gov